Tests tirzepatide in people with chronic kidney failure and obesity
Tests tirzepatide, a weight-lowering drug, in adults with kidney failure and obesity.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure
Key facts
- Where
- Tehran, IranSee the site
Where in Iran
- Nooshin DaliliTehran, IranNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shahid Beheshti University of Medical Sciences
- Trial code
- NCT07176663
- Record updated
- 15 December 2025
- Original description
Diabetes management presents a complex clinical scenario marked by several challenges, especially in chronic kidney failure. These include navigating potential drug interactions between oral antidiabetic therapies and other agents. Furthermore, these patients may experience various adverse drug effects, such as lactic acidosis, electrolyte abnormalities such as hypomagnesemia, fluid retention, and lipid derangements, which can further augment overall morbidity. Consequently, many patients receive insulin. However, prolonged intensive insulin therapy may be linked to several adverse outcomes, including an increased risk of hypoglycemia and weight gain.Read full original descriptionShow less
Safety and Effectiveness of Tirzepatide(Spartina )in Chronic Kidney Failure a Single-center Study
Diabetes management presents a complex clinical scenario marked by several challenges, especially in chronic kidney failure. These include navigating potential drug interactions between oral antidiabetic therapies and other agents. Furthermore, these patients may experience various adverse drug effects, such as lactic acidosis, electrolyte abnormalities such as hypomagnesemia, fluid retention, and lipid derangements, which can further augment overall morbidity. Consequently, many patients receive insulin. However, prolonged intensive insulin therapy may be linked to several adverse outcomes, including an increased risk of hypoglycemia and weight gain.
Hence, a common practice is to transition to medications commonly used other populations of patients. With their established benefits on glycemic control, cardiovascular health, renal benefits, and weight management, in conjunction with the aforementioned adverse effects associated with other oral antidiabetics agents, glucagon-like peptide-1 receptor agonists have emerged as an attractive therapeutic option for patients with kidney failure.
Inclusion: age ≥18 years and history of diabetes or BMI over 27.
Exclusion: Previous usage of similar therapy for less than 3 months owing to the inability to capture all efficacy and safety endpoints within this brief timeframe and/or nonadherence to tirzepatide therapy.